13,299 reports of this reaction
1.6% of all Dupixent reports
#15 most reported adverse reaction
SKIN EXFOLIATION is the #15 most commonly reported adverse reaction for Dupixent, manufactured by Sanofi-Aventis U.S. LLC. There are 13,299 FDA adverse event reports linking Dupixent to SKIN EXFOLIATION. This represents approximately 1.6% of all 838,442 adverse event reports for this drug.
Patients taking Dupixent who experience skin exfoliation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SKIN EXFOLIATION is a less commonly reported adverse event for Dupixent, but still significant enough to appear in the safety profile.
In addition to skin exfoliation, the following adverse reactions have been reported for Dupixent:
The following drugs have also been linked to skin exfoliation in FDA adverse event reports:
SKIN EXFOLIATION has been reported as an adverse event in 13,299 FDA reports for Dupixent. This does not prove causation, but indicates an association observed in post-market surveillance data.
SKIN EXFOLIATION accounts for approximately 1.6% of all adverse event reports for Dupixent, making it a notable side effect.
If you experience skin exfoliation while taking Dupixent, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.